Quest Diagnostics Incorporated $DGX Shares Bought by Linden Thomas Advisory Services LLC

Linden Thomas Advisory Services LLC grew its position in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 0.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,602 shares of the medical research company’s stock after purchasing an additional 89 shares during the period. Linden Thomas Advisory Services LLC’s holdings in Quest Diagnostics were worth $2,084,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of DGX. Brighton Jones LLC acquired a new stake in shares of Quest Diagnostics during the 4th quarter worth about $323,000. GAMMA Investing LLC boosted its stake in shares of Quest Diagnostics by 38.3% during the 1st quarter. GAMMA Investing LLC now owns 2,630 shares of the medical research company’s stock worth $445,000 after purchasing an additional 728 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its stake in shares of Quest Diagnostics by 23.5% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 8,908 shares of the medical research company’s stock worth $1,507,000 after purchasing an additional 1,693 shares during the last quarter. Spire Wealth Management boosted its stake in shares of Quest Diagnostics by 19.1% during the 1st quarter. Spire Wealth Management now owns 1,357 shares of the medical research company’s stock worth $230,000 after purchasing an additional 218 shares during the last quarter. Finally, Golden State Wealth Management LLC boosted its stake in shares of Quest Diagnostics by 157.3% during the 1st quarter. Golden State Wealth Management LLC now owns 193 shares of the medical research company’s stock worth $33,000 after purchasing an additional 118 shares during the last quarter. 88.06% of the stock is owned by institutional investors and hedge funds.

Quest Diagnostics Trading Down 0.4%

NYSE DGX opened at $182.51 on Friday. Quest Diagnostics Incorporated has a one year low of $148.70 and a one year high of $197.55. The company’s 50 day moving average price is $182.99 and its 200 day moving average price is $176.89. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.99 and a current ratio of 1.13. The firm has a market capitalization of $20.30 billion, a price-to-earnings ratio of 21.42, a PEG ratio of 2.40 and a beta of 0.56.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings data on Tuesday, October 21st. The medical research company reported $2.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.51 by $0.09. The company had revenue of $2.82 billion for the quarter, compared to analyst estimates of $2.73 billion. Quest Diagnostics had a net margin of 8.91% and a return on equity of 15.47%. The business’s quarterly revenue was up 13.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.30 earnings per share. Quest Diagnostics has set its FY 2025 guidance at 9.760-9.840 EPS. On average, sell-side analysts predict that Quest Diagnostics Incorporated will post 9.7 EPS for the current year.

Quest Diagnostics Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, October 20th. Stockholders of record on Friday, October 3rd were paid a dividend of $0.80 per share. The ex-dividend date was Friday, October 3rd. This represents a $3.20 dividend on an annualized basis and a dividend yield of 1.8%. Quest Diagnostics’s dividend payout ratio (DPR) is currently 37.56%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Robert W. Baird reissued a “neutral” rating and issued a $194.00 target price on shares of Quest Diagnostics in a research report on Monday, August 25th. Leerink Partners raised their target price on shares of Quest Diagnostics from $203.00 to $210.00 and gave the stock an “outperform” rating in a research report on Tuesday. Wall Street Zen raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Saturday. Mizuho raised their target price on shares of Quest Diagnostics from $190.00 to $210.00 and gave the stock an “outperform” rating in a research report on Friday, October 17th. Finally, Deutsche Bank Aktiengesellschaft raised their target price on shares of Quest Diagnostics from $160.00 to $178.00 and gave the stock a “hold” rating in a research report on Wednesday, July 23rd. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, Quest Diagnostics currently has an average rating of “Moderate Buy” and an average target price of $196.31.

Insider Activity

In other news, SVP Patrick Plewman sold 1,975 shares of Quest Diagnostics stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $185.00, for a total transaction of $365,375.00. Following the sale, the senior vice president owned 15,269 shares in the company, valued at $2,824,765. This trade represents a 11.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Karthik Kuppusamy sold 2,210 shares of Quest Diagnostics stock in a transaction on Thursday, July 31st. The stock was sold at an average price of $170.00, for a total transaction of $375,700.00. Following the completion of the sale, the senior vice president owned 8,450 shares of the company’s stock, valued at approximately $1,436,500. This trade represents a 20.73% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 54,668 shares of company stock worth $9,917,788. Company insiders own 8.16% of the company’s stock.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.